# Raviv Pryluk

> Raviv Pryluk is the CEO and co-founder of PhaseV, a Boston-based clinical-development software company. Trained first as an aerospace engineer and later as a computational neuroscientist, he spent more than 15 years in defense and technology, moved into biotech operations at Immunai, and co-founded PhaseV in 2023. His work now centers on using causal machine learning, simulation, and adaptive methods to help clinical-development teams make decisions before and during trials.

- **Role:** CEO and Co-Founder at PhaseV
- **Organizations:** PhaseV, Immunai, Weizmann Institute of Science, Technion - Israel Institute of Technology, Israel Aerospace Industries, Israel Defense Forces
- **Education:** B.Sc. in Aerospace, Aeronautical and Astronautical Engineering, Technion - Israel Institute of Technology, M.Sc. in Aerospace, Aeronautical and Astronautical Engineering, Technion - Israel Institute of Technology, Ph.D. in Computational Neuroscience, Weizmann Institute of Science
- **Known for:** Co-founded PhaseV and led the company through a $50 million Series A in 2025, bringing total disclosed funding to $65 million., Received the Weizmann Institute's John F. Kennedy Prize for outstanding Ph.D. researchers., Graduated cum laude from the Technion and magna cum laude from the Weizmann Institute, according to PhaseV's official biography.

## Career timeline

- **2009-2021** — Held technical and leadership roles across defense and technology, including the Israel Defense Forces and Israel Aerospace Industries.
- **2016-2019** — Completed doctoral work in computational neuroscience at the Weizmann Institute, studying neural coding and social signals.
- **2019-2021** — Published neuroscience research in journals including Cell, PNAS, Nature, eNeuro, and Neuron.
- **2021-2023** — Worked at Immunai in leadership roles spanning discovery and validation, operations, and analytics, ultimately serving as SVP of Operations and Analytics.
- **2023** — Co-founded PhaseV with Elad Berkman and became CEO.
- **2024** — Chaired a DIA Global Annual Meeting session on machine learning and clinical-trial simulation and co-authored research on causal responder detection.
- **2025** — Led PhaseV through a $50 million Series A co-led by Accel and Insight Partners, bringing disclosed funding to $65 million.
- **2026** — Spoke publicly about closing the lag between clinical-data collection and analysis-ready data, and presented on AI-assisted trial optimization at the Joint Statistical Meetings.

## Achievements

- Co-founded PhaseV and led the company through a $50 million Series A in 2025, bringing total disclosed funding to $65 million.
- Received the Weizmann Institute's John F. Kennedy Prize for outstanding Ph.D. researchers.
- Graduated cum laude from the Technion and magna cum laude from the Weizmann Institute, according to PhaseV's official biography.
- Co-authored peer-reviewed research published in Cell, Nature, PNAS, eNeuro, and Neuron.
- Co-authored Causal Responder Detection research applying causal machine learning to heterogeneous treatment effects.
- Built and led multidisciplinary technology, analytics, and operations teams in defense, biotech, and clinical-development software.

## Latest updates

- **2026-08** — In an Applied Clinical Trials Q&A, Pryluk argued that real-time trial monitoring depends on faster cleaning, mapping, and standardization of clinical data, not merely faster data streaming.
- **2026-08** — Presented on AI and machine-learning tools for sample-size optimization, subgroup detection, and clinical operations at the Joint Statistical Meetings in Boston.
- **2025-07** — PhaseV announced a clinical-operations AI platform focused on site selection and trial-performance monitoring.
- **2025-05** — PhaseV raised a $50 million Series A co-led by Accel and Insight Partners; the company said the capital would support product expansion, commercial partnerships, and growth in the United States and Europe.
- **2025-03** — Pryluk discussed PhaseV at Calcalist's Mind the Tech conference in New York after the company was named to Qumra Capital's list of Israeli startups to watch in 2025.

## Links

- Website: https://www.phasevtrials.com/
- LinkedIn: https://www.linkedin.com/in/raviv-pryluk-418763216/

---

Profile page: https://yespress.io/raviv-pryluk
Published by YesPress — https://yespress.io
Last updated: 2026-09-27